Doctors have been left astonished after an experimental cancer drug proved to have a remarkable success rate.
The drug dostarlimab appeared to cure practically every patient during a clinical trial at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York.
In the study, the cancer drug was given to 18 people with a type of rectal cancer every three weeks for six months.